Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CLBTBearishLegalnews

High materiality7/10

Kaplan Fox Investigates Cellebrite Securities Violations Following ARR Miss and CEO Change

Sep 16, 2026, 11:19 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The disclosure implies legal risk and potential costs; historically, securities investigations into constituents can trigger volatility and multiple compression, particularly when tied to revenue milestones and leadership changes. However, absence of concrete allegations limits immediate, material changes absent new facts.

AI summary

What happened, with direct paths to the underlying reporting

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations involving Cellebrite (CLBT) after the Q2 ARR miss and a $15 million midpoint guidance cut, alongside an abrupt CEO change. The stock dropped about 29% to $10.80 on August 13, 2026. The investigation introduces legal risk, but no new substantive facts are disclosed yet, leaving the ultimate impact uncertain.

Kaplan Fox investigating potential securities violations for Cellebrite (CLBT). No firm-made conclusions yet.
Q2 ARR $507.8M; guidance cut midpoint about $15M. CEO change announced.
Stock fell 29% to $10.80 on Aug 13, 2026. Catalyst: results/CEO shift.
Investors should monitor for updates and potential filings. Impact hinges on new facts.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.